FDA approved a new monthly dosing schedule for Janssen’s RYBREVANT FASPRO, a bispecific antibody that targets EGFR and MET in patients with EGFR‑mutated non‑small cell lung cancer. The approval allows patients to switch to once‑monthly subcutaneous injections as early as week 5 when the drug is combined with the oral EGFR inhibitor LAZCLUZE. The new schedule delivers the same objective response rates and overall survival benefits as the previously approved bi‑weekly regimen while cutting clinic visits and administration‑related reactions by five‑fold.
The approval expands the convenience and adherence profile of RYBREVANT FASPRO, positioning Janssen to capture a larger share of the growing EGFR‑targeted therapy market. The market is projected to reach multi‑billion‑dollar valuations over the next decade, with the EGFR‑mutated lung cancer treatment segment expected to reach USD 39.2 billion by 2036 at a 9.3% CAGR. By offering a monthly dosing option, Janssen gains a competitive edge over rivals that provide only bi‑weekly schedules.
The monthly dosing schedule builds on the subcutaneous formulation that received FDA approval on December 17, 2025, which already reduced administration time and reactions. The new schedule is supported by data from studies such as PALOMA‑2 and PALOMA‑3, which demonstrated comparable efficacy and safety to the bi‑weekly regimen.
Investors reacted positively to the approval, citing the convenience advantage and potential market‑share gains. The decision underscores Janssen’s strategy to enhance patient‑centric treatment options and strengthen its oncology portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.